This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|February 21, 2017
Abzena Signs Antibody Manufacturing Development Agreement with UCL
Author(s)BioPharm International Editors
Under the agreement, Abzena will manufacture magacizumab, an antibody created using the ‘Abzena inside’ Composite Human Antibody technology.
Advertisement
Abzena, a CDMO providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed an agreement with University College London (UCL), United Kingdom, to manufacture magacizumab, an antibody created using the ‘Abzena inside’ Composite Human Antibody technology.
In previous agreements with UCL, Abzena conducted the antibody humanization and developed the manufacturing cell line for magacizumab. Under this new service agreement, Abzena will manufacture magacizumab at its biomanufacturing facility in San Diego, CA, US. For Abzena, this program is the first to proceed with Abzena through each of the phases of humanization, cell line development, and into manufacture.
UCL Institute of Ophthalmology is developing magacizumab for the treatment of neovascular (or wet) age-related macular degeneration (AMD), a condition that affects older people and can lead to loss of vision due to abnormal blood vessel growth. The antibody targets LRG1 (leucine-rich alpha-2-glycoprotein 1), which researchers at UCL identified as having a role in promoting the growth of pathological blood vessels. The project is funded by the Medical Research Council’s Developmental Pathway Funding Scheme. UCL Business, the technology commercialization arm of UCL, currently owns the patents for magacizumab. Under the previous antibody humanization agreement with UCL, Abzena will receive a milestone payment once the antibody enters clinical development.
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
3
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
4
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
5